SOUTHLAKE, Texas--(BUSINESS WIRE)--HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 Arab Health show at the Dubai International Convention and Exhibition Centre in Dubai, UAE, 29 January through 01 February, 2018.
HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease. Its MyoVista® hsECG™ (high sensitivity ECG) device is designed to significantly improve the sensitivity of a diagnostic electrocardiology device in detecting ischemic and structural heart disease at an early stage. Through the patented use of Continuous Wavelet Transform digital signal processing it measures the heart’s energy during its cardiac cycle. Recent clinical trials demonstrate MyoVista’s ability to detect cardiac dysfunction in the diastolic phase, which is known as Diastolic Dysfunction. The MyoVista hsECG includes all the conventional information of a full featured 12-lead resting ECG plus new energy related informatics assisting in the early detection of heart disease.
HeartSciences was selected as a Fierce Innovation Award Finalist in December 2017 for its innovative MyoVista® hsECG™ device. Finalists were selected from a highly competitive list of innovators by a distinguished panel of judges. All applications were evaluated based on the following criteria: Competitive Advantage, Financial Impact/Value, Market Need, and Overall Innovation. Applicants with the top 3 scores in each category were selected as finalists. Life Sciences Edition 2017 is an awards program from the well-known e-publisher of FierceBiotech and FiercePharma.
HeartSciences is advancing the field of electrocardiology by bridging today’s “diagnostic gap” in cardiac care by developing new low-cost effective solutions that assist in identifying at-risk, and often asymptomatic patients in the early stages of heart disease.
HeartSciences’ MyoVista® hsECG™ Cardiac Testing Device is a new 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Its patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on abnormalities related to cardiac energy levels in addition to providing conventional ECG information.
In addition to the proprietary informatics, the MyoVista hsECG device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms.
HeartSciences (formerly known as Heart Test Laboratories) is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.